Sign In
Buy ORGO
$2.33
+0.0900 (+4.02%)
At Close: Jun 03, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
10:00am, Thursday, 29'th Jan 2026
NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Organogenesis Holdings Inc. ("Organogenesis" or the "Company") (NASDAQ: ORGO). Such investors a
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
10:00am, Thursday, 22'nd Jan 2026
NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Organogenesis Holdings Inc. ("Organogenesis" or the "Company") (NASDAQ: ORGO). Such investors a
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
04:11pm, Tuesday, 20'th Jan 2026
NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Organogenesis Holdings Inc. (“Organogenesis” or the “Company”) (NASDAQ: ORGO). Such
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
10:00am, Thursday, 15'th Jan 2026
NEW YORK, Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Organogenesis Holdings Inc. ("Organogenesis" or the "Company") (NASDAQ: ORGO). Such investors a
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
04:07pm, Tuesday, 13'th Jan 2026
NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Organogenesis Holdings Inc. (“Organogenesis” or the “Company”) (NASDAQ: ORGO). Such
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
10:00am, Thursday, 08'th Jan 2026
NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Organogenesis Holdings Inc. ("Organogenesis" or the "Company") (NASDAQ: ORGO). Such investors ar
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
12:49pm, Tuesday, 06'th Jan 2026
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Organogenesis Holdings Inc. (“Organogenesis” or the “Company”) (NASDAQ: ORGO). Such
Organogenesis (NASDAQ:ORGO) Trading Down 5% – Time to Sell?
05:46am, Sunday, 04'th Jan 2026
Organogenesis (NASDAQ: ORGO - Get Free Report) shares fell 5% on Friday. The stock traded as low as $4.90 and last traded at $4.9210. 125,954 shares traded hands during trading, a decline of 92% from
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
04:38pm, Tuesday, 30'th Dec 2025
NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Organogenesis Holdings Inc. (“Organogenesis” or the “Company”) (NASDAQ: ORGO). Such
Contrasting Organogenesis (NASDAQ:ORGO) & Catalyst Pharmaceuticals (NASDAQ:CPRX)
01:14am, Sunday, 28'th Dec 2025
Catalyst Pharmaceuticals (NASDAQ: CPRX - Get Free Report) and Organogenesis (NASDAQ: ORGO - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two co
Organogenesis Announces Initiation of Biologics License Application for ReNu®
04:05pm, Tuesday, 23'rd Dec 2025
Initial modules submitted to FDA under rolling review; final modules expected in the first half of 2026 Initial modules submitted to FDA under rolling review; final modules expected in the first half
Assenagon Asset Management S.A. Has $20.49 Million Stock Position in Organogenesis $ORGO
03:27am, Saturday, 20'th Dec 2025
Assenagon Asset Management S.A. lifted its holdings in Organogenesis (NASDAQ: ORGO) by 69.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities a
Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain
04:25pm, Monday, 15'th Dec 2025
Clinical Development Program Appropriate for Rolling BLA Submission Expected by the End of 2025 CANTON, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading
Organogenesis: High-Tech Skin Substitute Company On Sale
07:26am, Thursday, 11'th Dec 2025
Organogenesis receives a Buy rating, driven by Q3/2025 beats, raised guidance, and favorable CMS payment reform for skin substitute products. AWC revenues grew 31% year-over-year; 2025 guidance calls
Organogenesis Holdings Inc. (ORGO) Q3 2025 Earnings Call Transcript
04:36pm, Friday, 07'th Nov 2025
Organogenesis Holdings Inc. ( ORGO ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Gary Gillheeney - President, CEO, Chair of the Board David Francisco - Chief Financial Offi
